Business Description
Arrowhead Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US04280A1007
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.86 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 0.74 | |||||
Debt-to-EBITDA | -0.44 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0.18 | |||||
Beneish M-Score | -4.9 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 37.2 | |||||
3-Year EBITDA Growth Rate | -23.9 | |||||
3-Year EPS without NRI Growth Rate | -31.7 | |||||
3-Year FCF Growth Rate | -42.5 | |||||
3-Year Book Growth Rate | -17.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.18 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.96 | |||||
9-Day RSI | 34.21 | |||||
14-Day RSI | 37.01 | |||||
6-1 Month Momentum % | -5.82 | |||||
12-1 Month Momentum % | -37.29 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.73 | |||||
Quick Ratio | 3.73 | |||||
Cash Ratio | 3.46 | |||||
Days Sales Outstanding | 56.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | -1.17 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -164.75 | |||||
Net Margin % | -163.32 | |||||
FCF Margin % | -221.58 | |||||
ROE % | -91.59 | |||||
ROA % | -37.38 | |||||
ROIC % | -81.36 | |||||
ROC (Joel Greenblatt) % | -100.15 | |||||
ROCE % | -40.11 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.11 | |||||
PB Ratio | 14.8 | |||||
Price-to-Tangible-Book | 15.76 | |||||
EV-to-EBIT | -9.35 | |||||
EV-to-Forward-EBIT | -6.64 | |||||
EV-to-EBITDA | -9.84 | |||||
EV-to-Forward-EBITDA | -6.19 | |||||
EV-to-Revenue | 14.53 | |||||
EV-to-Forward-Revenue | 34.7 | |||||
EV-to-FCF | -6.56 | |||||
Price-to-Median-PS-Value | 0.34 | |||||
Earnings Yield (Greenblatt) % | -10.7 | |||||
FCF Yield % | -14.68 |